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Several diagnostic imaging methodologies are available for the clinical
evaluation of sarcoidosis, but all have their limitations. FDG PET/CT is
frequently used, but this technique does not provide optimal results in all
cases. Novel radiopharmaceuticals aimed at other disease targets may be
helpful, particularly in cardiac sarcoidosis when FDG PET/CT has a low
diagnostic accuracy, due to difficulties in preparing the patients who should
use a specific diet combined with prolonged fasting. 68Ga-labeled somatostatin
based receptor hybrid imaging is a potential alternative to FDG PET/CT.
This short communication provides a rapid overview of initial findings
concerning the application of 68Ga-labeled somatostatin based receptor hybrid
imaging in the diagnosis of (cardiac) sarcoidosis activity.
Keywords: Sarcoidosis, Cardiac, PET/CT, Somatostatin receptor imagingIntroduction
Sarcoidosis is a granulomatous disorder of unknown etiology and is most com-
monly affecting lymph nodes in the mediastinum, hili and the parenchyma of the
lungs, but it can involve any organ system (Baughman et al., 2001). Sarcoidosis
affects approximately 10 out of 100,000 persons each year (Ungprasert et al.,
2016). Cardiac sarcoidosis is reported to involve only 2% to 5% of patients with
systemic sarcoidosis (Baughman et al., 2001; Lynch et al., 2014), but autopsy
studies indicate a considerably higher prevalence of around 27% (Perry & Vuitch,
1995; Silverman et al., 1978).
The clinical presentation of cardiac sarcoidosis covers a large variability in
arrhythmogenicity. This ranges from being asymptomatic to heart block, heart
failure, complex arrhythmias and sudden cardiac death. The Heart Rhythm
Society (HRS) has published an expert consensus statement which recommends
that patients with sarcoidosis proved by biopsy and possible clinical cardiac
manifestations should be screened for cardiac involvement (Birnie et al., 2014).
Non-invasive, specific imaging is needed to evaluate the cardiac sarcoid
involvement.The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
icense (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
rovided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
ndicate if changes were made.
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Several diagnostic imaging techniques for diagnosing sarcoidosis are available. Chest
imaging plays a central role in the diagnosis and monitoring of sarcoidosis. Chest X-ray
is usually the initial approach to evaluate the parenchymal and mediastinal and hilar
lymph node involvement. High-resolution CT (HRCT) is more accurate in visualizing
the various manifestations of pulmonary sarcoidosis, including its complications, but
lacks specificity for mediastinal lymph node involvement. 18F–fluorodeoxyglucose posi-
tron emission tomography, combined with computed tomography (CT) (FDG PET/
CT) is emerging as a useful adjunct in complicated cases of sarcoidosis, particularly for
identifying occult (extra)thoracic disease activity, including targets for tissue diagnosis,
and has also been used as a non-invasive marker of disease severity especially in Stage
IV pulmonary fibrosis, therapy evaluation, and in cardiac sarcoidosis (CS). FDG PET/
CT has been reported to display variable sensitivity and specificity for detecting CS,
due to the absence of a specific diet and of prolonged fasting in some studies.(Youssef
et al., 2012). Focal heterogeneous FDG uptake in the myocardium within the appropri-
ate clinical context indicates cardiac involvement. The clinical application of FDG PET/
CT to evaluate CS has several limitations. Myocardial FDG uptake can be highly
variable and special preparation is required to suppress the glucose metabolism of the
myocardial cells in order to eliminate physiological background myocardial FDG uptake
as much as possible. Further pre-test optimization strategies are required, such as
dietary modification or unfractionated heparin, as solely fasting may not be sufficient to
suppress myocardial FDG uptake (Harisankar et al., 2011; Scholtens et al., 2016;
Williams & Kolodny, 2008). FDG PET/CT may also show focal and heterogeneous up-
take in the heart due to infarction or ischemia rather than CS, but in general, coronary
artery disease is ruled out before by conventional diagnostics.
Specific radiopharmaceuticals without physiological myocardial background activity
may be of additional value. 68Ga-labeled somatostatin based PET imaging is already
available and used for other (oncological) applications, but may be promising to be
applied in the diagnosis of (cardiac) sarcoidosis.
The somatostatin receptor subtype 2 (SSTR2) is highly expressed in sarcoid granulomas.
This high SSTR2 receptor expression is beneficial for somatostatin receptor scintigraphy
(SRS) using 111In-DTPA-D-Phe1-octreotide (Kamphuis et al., 2015). 111In-DTPA-D-Phe1-
octreotide and several 68Gallium-labeled somatostatin analogues which are used for PET
imaging possess a high SSTR2 affinity (Gormsen et al., 2016). 68Ga-DOTA-NaI-octreotide
(DOTANOC), 68Ga-DOTA-DPhe(Baughman et al., 2001)-Tyr
3-octreotate (DOTATATE)
or 68Ga-DOTA-D-Phe-Tyr-octreotide (DOTATOC) could be used as alternatives to the
non-specific tracer FDG in patients with suspected (cardiac) sarcoidosis. Epithelioid cells,
giant cells, and macrophages that can be found in sarcoid granulomas highly express
SSTRs (more specifically, SSTR2A) on their surface (ten Bokum et al., 1999). These
somatostatin analogs have different affinities to the different subtypes of the SSTR recep-
tor. 68Ga-DOTANOC has a high affinity to both SSTR2 and 5 (Prasad & Baum, 2010),
whereas 68Ga-DOTATOC has mainly high affinity to SSTR2 (Nobashi et al., 2016). The
main advantage of these tracers is the absence of uptake in the normal heart, due to the
lack of SSTR2 expression on the myocardial cell. The resulting high signal-to-noise ratio
is beneficial for 68Ga- SSTR2 imaging, allowing a more straightforward and reproducible
image interpretation, even by less experienced readers/physicians as compared to FDG
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the individual patient (whole body composition), which can help in assessing whether
treatment with cold or hot somatostatin analogs could be beneficial. Finally, the benefit of
generator produced 68Ga isotopes bypasses the dependency of a cyclotron.Future
The Japanese Ministry of Health and Welfare (JMHW) has issued criteria for the diag-
nosis of sarcoidosis. However, these criteria do not mention SSTR2 PET imaging, and
also exclude the use of FDG PET/CT in CS (Jpn Ministry Health Welfare, 2007). The
HRS recommends FDG PET/CT as diagnostic in CS, but is not mentioning SSTR2
imaging. A low number of mainly small studies has reported on the use of SSTR2 PET/
CT imaging in CS (Gormsen et al., 2016; Nobashi et al., 2016; Lapa et al., 2016). Larger,
randomized prospective studies should confirm the value of SSTR2 PET/CT imaging,
compared to conventional imaging such as cardiac FDG PET and cardiac magnetic
resonance imaging (CMR).
More recent studies have highlighted the utility of integrated FDG PET/MRI in CS
(Hanneman et al., 2017; Schneider et al., 2014; Wada et al., 2015). In general, the detec-
tion of pathologic glucose metabolism using FDG-PET could improve the specificity of
CMR. Late gadolinium enhancement can be measured semi-quantitatively using con-
tour tracing, and more specifically, T2 mapping can be performed to measure disease
activity (edema) which can be used in therapy monitoring (Yang et al., 2014). T1 map-
ping (tissue characterization) can also quantify the amount of fibrosis and inflammation
(edema) in CS (Puntmann et al., 2017). Combined FDG and CMR imaging with hybrid
PET/MRI may be of value.
But does the same hold true for combined SSTR2 PET/MRI imaging? Future studies
will be necessary to provide evidence for the clinical application of PET/MRI in CS
(Nensa et al., 2015).
At the moment, it is unclear whether SSTR2 PET/CT imaging is more beneficial in
acute or chronic sarcoidosis. The initial impression is that SSTR2 PET/CT imaging is
most helpful in the acute phase of sarcoidosis. In the chronic phase, fibrotic tissue is
formed. Fibrotic tissue lacks substantial SSTR2 expression, potentially resulting in a
low signal in SSTR2 PET/CT (Nobashi et al., 2016). It’s questionable if SSTR2 PET/CT
imaging will then be better as compared to FDG. FDG activity and SSTR expression
are different in these phases. The most optimal approach is using FDG for acute
inflammation at first diagnosis of CS or suspicion of recurrence or relapse, because of
the impact on the therapeutic management. The chronic phase should be covered by
the CMR. An example of this is shown in Fig. 1, of a patient familiar with general
sarcoidosis, including cardiac involvement. PET/CT visualized high FDG uptake and
moderate 68Ga-SSTR2 uptake. Further investigations are needed to assess in which
phase of sarcoidosis SSTR2 PET/CT imaging should be applied.
Applying this 68Ga-SSTR2 in the chronic phase (relapse/recurrence) of (cardiac)
sarcoidosis seems to be a potential role, maybe combined with CMR, using hybrid
PET/MRI. Another option is application in patients that are unable/not willing to pre-
pare for a FDG PET/CT scan by subjecting themselves to a low-carbohydrate/high fat
diet and fasting regime.
Fig. 1 68Ga-Dotatoc whole body PET (a) in a 56-year old woman with chronic (cardiac) sarcoidosis.
Increased uptake is visible in the lymph nodes located at the right-sideof the mediastinum and in lung hilar
tissue. 68Ga-Dotatoc PET/CT uptake (b) is visible in the left ventricle of the heart (lateral, basal, septal) and
the anterior part of the right ventricle. The same distribution pattern is visible on FDG whole body (c) and
cardiac PET (d), but is more intense. Apparently FDG PET was more helpful than 68Ga-Dotatoc in the chronic
phase of sarcoidosis in this patient
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approach. High SSTR2 receptor expression suggests that somatostatin treatment may
be an option in patients that are resistant to conventional treatment with corticosteroids.
In these patients 68Ga-SSTR2 imaging might be helpful to evaluate and to quantify the
SSTR2 expression and may predict the effect of treatment with somatostatin.
In conclusion, 68Ga labeled SSTR2 PET/CT seems an interesting alternative to FDG
PET/CT in (cardiac) sarcoidosis, since these modalities have different imaging targets.
Additional studies comparing these radiopharmaceuticals are needed, particularly to
evaluate in which phase of sarcoidosis (acute or chronic) 68Ga labeled SSTR2 PET/CT
will be more beneficial than FDG.
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